[Federal Register Volume 61, Number 96 (Thursday, May 16, 1996)] [Notices] [Page 24804] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 96-12256] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Advisory Committee on Immunization Practices: Announcement of Meeting and Request for Comments on Draft Poliomyelitis Statement In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting. Name: Advisory Committee on Immunization Practices (ACIP). Times and Dates: 8:30 a.m.-6 p.m., June 19, 1996. 8:30 a.m.-2:45 p.m., June 20, 1996. Place: CDC, Auditorium B, Building 2, 1600 Clifton Road, NE, Atlanta, Georgia 30333. Status: Open to the public, limited only by the space available. Purpose: The Committee is charged with advising the Director, CDC, on the appropriate uses of immunizing agents. Matters to be Discussed: The Committee will discuss, among other items, the revision of the ACIP recommendation on poliomyelitis. Because of the considerable interest in the revised ACIP recommendation on poliomyelitis, there will be a public comment period on the morning of June 19, not to exceed three hours, during which members of the public will be able to address the ACIP members and executive staff of the CDC on the draft ACIP poliomyelitis prevention statement. This statement introduces a sequential schedule of inactivated poliovirus vaccine (IPV) followed by oral poliovirus vaccine (OPV) and includes the options of using any of three schedules: OPV alone, IPV alone or the sequential IPV--OPV schedule. Other topics to be discussed at the meeting include: measles, mumps, rubella (MMR) policy statement; MMR vaccination of HIV- infected persons; a draft statement on acellular pertussis vaccine; the use of single antigen tetanus toxoid; a draft statement for rabies post-exposure treatment; an immunization update on varicella vaccine; a draft statement on reminder/recall systems; and achieving consistency among policy statements and vaccine package inserts. Other matters of relevance among the Committee's objectives may be discussed. Agenda items are subject to change as priorities dictate. Copies of the revised draft ACIP recommendation, ``Poliomyelitis Prevention in the United States: Introduction of A Sequential Schedule of Inactivated Poliovirus Vaccine (IPV) Followed by Oral Poliovirus Vaccine (OPV),'' are available to the public by notifying the contact person. Copies may be sent electronically upon request. Anyone wishing to make an oral presentation should submit their request, in writing, to the contact person by close of business June 3, 1996. The request should include the name, address, and telephone number of the participant; the approximate time needed; and a copy of the presentation or a brief summary of the topic to be presented. Depending on the number of requests, up to six minutes will be allowed for each oral presentation. Anyone wishing to submit for consideration written comments regarding the revised ACIP recommendation on poliomyelitis prevention should submit the written comments to the contact person by June 13, 1996. Contact Person for More Information: Gloria A. Kovach, Committee Management Specialist, CDC (16-4346), 1600 Clifton Road, NE, M/S D50, Atlanta, Georgia 30333, Telephone 404/639-7250. Dated: May 10, 1996. Nacny C. Hirsch, Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC). [FR Doc. 96-12256 Filed 5-15-96; 8:45 am] BILLING CODE 4163-18-M